Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2021 · 10-Q
Revenue$209.49M$209.49M−17.1% vs Q2 2020 Net Income$48.10M$48.10M+28.3% vs Q2 2020 EPS Diluted$0.94$0.94+30.6% vs Q2 2020 Gross Profit$105,744,000−16.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$29,155,000−2.5% Free Cash Flowderived$20,816,000+1.9% Margins · derivedGross margin50.5%+0.2 pt vs Q2 2020
Operating margin28.1%+8.4 pt vs Q2 2020
Net margin23.0%+8.1 pt vs Q2 2020
ended Sep 26, 2020 · filed Nov 4, 2020 · 39 d after period end